Pharmaceutical

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Dec 20, 2023 - 18:00
GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Myelodysplastic Syndrome.
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood...

Next Article

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Dis...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Abortion policy in the spotlight, DeSantis’ importation showdown, and new price hike analysis

STAT+: Abortion policy in the spotlight, DeSantis’ impo...

Aug 27, 2023

AI insight at BIO, Google and Mayo Clinic’s latest effort, & $13 million for health workforce tech

AI insight at BIO, Google and Mayo Clinic’s latest effo...

Jun 8, 2023

His book on the opioid crisis flopped in 2003. It now has a new life on Netflix

His book on the opioid crisis flopped in 2003. It now h...

Jul 28, 2023